0001564590-21-054499 | 10-Q | XBRL Viewer

Label	Element	Value
License Agreement Term	asmb_LicenseAgreementTerm	2 years
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain	$ 1,000
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain	$ 7,000
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	2,109,140
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	315,102
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	315,102
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	2,424,242
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	0
Number Of Warrants Exercised	asmb_NumberOfWarrantsExercised	0
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss	$ 16,000
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss	4,000
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	(1,348,000)
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	(2,959,000)
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	1,611,000
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	0
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	(1,625,000)
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	277,000
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	0
Restructuring And Related Cost Incurred Cost Benefit	asmb_RestructuringAndRelatedCostIncurredCostBenefit	0
Cash And Cash Equivalent Gross Unrealized Gain	asmb_CashAndCashEquivalentGrossUnrealizedGain	0
Cash And Cash Equivalent Gross Unrealized Gain	asmb_CashAndCashEquivalentGrossUnrealizedGain	0
Cash And Cash Equivalent Gross Unrealized Gain	asmb_CashAndCashEquivalentGrossUnrealizedGain	0
Cash And Cash Equivalent Gross Unrealized Gain	asmb_CashAndCashEquivalentGrossUnrealizedGain	0
Cash And Cash Equivalent Gross Unrealized Gain	asmb_CashAndCashEquivalentGrossUnrealizedGain	0
Cash And Cash Equivalent Gross Unrealized Loss	asmb_CashAndCashEquivalentGrossUnrealizedLoss	0
Cash And Cash Equivalent Gross Unrealized Loss	asmb_CashAndCashEquivalentGrossUnrealizedLoss	0
Cash And Cash Equivalent Gross Unrealized Loss	asmb_CashAndCashEquivalentGrossUnrealizedLoss	0
Cash And Cash Equivalent Gross Unrealized Loss	asmb_CashAndCashEquivalentGrossUnrealizedLoss	0
Cash And Cash Equivalent Gross Unrealized Loss	asmb_CashAndCashEquivalentGrossUnrealizedLoss	0
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue	187,215,000
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue	211,020,000
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan	asmb_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan	144,000
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan	asmb_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan	$ 467,000
Available For Sale Securities Maturity Term	asmb_AvailableForSaleSecuritiesMaturityTerm	less than two years
Increase Decrease In Accrued Clinical Expenses	asmb_IncreaseDecreaseInAccruedClinicalExpenses	$ (700,000)
Increase Decrease In Accrued Clinical Expenses	asmb_IncreaseDecreaseInAccruedClinicalExpenses	(375,000)
Milestone Payment	asmb_MilestonePayment	200,000
Fair Value Assets Between Levels Transfers Amount	asmb_FairValueAssetsBetweenLevelsTransfersAmount	0
Fair Value Assets Between Levels Transfers Amount	asmb_FairValueAssetsBetweenLevelsTransfersAmount	$ 0
Class Of Warrant Or Right Issuance Dates	asmb_ClassOfWarrantOrRightIssuanceDates	Dec. 16, 2019
Performance Milestone Payment	asmb_PerformanceMilestonePayment	$ 0
Incremental Costs	asmb_IncrementalCosts	3,500,000
Incremental Costs	asmb_IncrementalCosts	200,000
Incremental Costs	asmb_IncrementalCosts	800,000
Accrued Clinical Expenses Current	asmb_AccruedClinicalExpensesCurrent	3,744,000
Accrued Clinical Expenses Current	asmb_AccruedClinicalExpensesCurrent	4,444,000
Restructuring Charges For Remaining Payment Obligations Of Leased Equipment	asmb_RestructuringChargesForRemainingPaymentObligationsOfLeasedEquipment	1,400,000
Up Front Payments	asmb_UpFrontPayments	1,800,000
Accretion And Amortization Of Investments In Marketable Debt Securities	asmb_AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities	(398,000)
Accretion And Amortization Of Investments In Marketable Debt Securities	asmb_AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities	80,000
Increase Decrease In Operating Lease Liabilities	asmb_IncreaseDecreaseInOperatingLeaseLiabilities	(2,856,000)
Increase Decrease In Operating Lease Liabilities	asmb_IncreaseDecreaseInOperatingLeaseLiabilities	$ (3,382,000)
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Subject To Deferred Settlement	asmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlement	140,000
Initial Public Offering Value Of Shares Authorized	asmb_InitialPublicOfferingValueOfSharesAuthorized	$ 300,000,000.0
Initial Public Offering Value Of Shares Authorized	asmb_InitialPublicOfferingValueOfSharesAuthorized	$ 100,000,000.0
Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Shares	asmb_IssuanceOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares	315,013
Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants Shares	asmb_IssuanceOfCommonStockUponCashlessExerciseOfPreFundedWarrantsShares	2,423,634
Accrued Restructuring Charges Current	asmb_AccruedRestructuringChargesCurrent	$ 232,000
Accrued Restructuring Charges Current	asmb_AccruedRestructuringChargesCurrent	4,164,000
Accrued Restructuring Charges Current	asmb_AccruedRestructuringChargesCurrent	4,164,000
Accrued Restructuring Charges Current	asmb_AccruedRestructuringChargesCurrent	232,000
Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants	asmb_IssuanceOfCommonStockUponCashlessExerciseOfPreFundedWarrants	2,000
Issuance Of Common Stock Upon Cashless Exercise Of Pre Funded Warrants	asmb_IssuanceOfCommonStockUponCashlessExerciseOfPreFundedWarrants	(2,000)
Success Based Milestones Payment	asmb_SuccessBasedMilestonesPayment	35,000,000.0
Noncash Rent Expense	asmb_NoncashRentExpense	2,940,000
Noncash Rent Expense	asmb_NoncashRentExpense	3,463,000
Agreed To Pay Maximum Amount Development And Regulatory Costs	asmb_AgreedToPayMaximumAmountDevelopmentAndRegulatoryCosts	45,000,000.0
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost	187,230,000
Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost	asmb_CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost	$ 211,017,000
Number Of Approved Products	asmb_NumberOfApprovedProducts	0
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Subject To Deferred Settlement Weighted Average Remaining Contractual Terms	asmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodSubjectToDeferredSettlementWeightedAverageRemainingContractualTerms	1 month 6 days
Upfront Cash Payment Received	asmb_UpfrontCashPaymentReceived	$ 40,000,000.0
Clinical Trial Collaboration Costs Incurred	asmb_ClinicalTrialCollaborationCostsIncurred	0
Clinical Trial Collaboration Costs Incurred	asmb_ClinicalTrialCollaborationCostsIncurred	0
Research And Development Funding Charges	asmb_ResearchAndDevelopmentFundingCharges	500,000
Research And Development Funding Charges	asmb_ResearchAndDevelopmentFundingCharges	1,300,000
Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets	asmb_RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets	788,000
Remeasurement Of Lease Liabilities Arising From Modification Of Right Of Use Assets	asmb_RemeasurementOfLeaseLiabilitiesArisingFromModificationOfRightOfUseAssets	0
Potential Milestone Payments	asmb_PotentialMilestonePayments	500,000,000.0
Potential Milestone Payments	asmb_PotentialMilestonePayments	113,800,000
Potential Milestone Payments	asmb_PotentialMilestonePayments	385,000,000.0
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Amount	asmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairAmount	400,000
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Amount	asmb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairAmount	$ 1,200,000

Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Collaboration Agreement [Abstract]
Additions	$ 0	$ 40,000
Deductions	$ (6,254)	$ (68,061)

Print Document View Excel Document
Notes Details Collaboration Agreements - Schedule of Changes in Contract Liabilities (Details) Uncategorized Uncategorized Items - asmb-10q_20210930_htm.xml All Reports